JP2004534816A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004534816A5 JP2004534816A5 JP2003506898A JP2003506898A JP2004534816A5 JP 2004534816 A5 JP2004534816 A5 JP 2004534816A5 JP 2003506898 A JP2003506898 A JP 2003506898A JP 2003506898 A JP2003506898 A JP 2003506898A JP 2004534816 A5 JP2004534816 A5 JP 2004534816A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- chloro
- same
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 9
- 125000001246 bromo group Chemical group Br* 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 208000020401 Depressive disease Diseases 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- GTMLDEPLKLLIHD-UHFFFAOYSA-N 2-(5-chloro-2-ethyl-1h-indol-3-yl)-n,n-dimethylethanamine Chemical compound C1=C(Cl)C=C2C(CCN(C)C)=C(CC)NC2=C1 GTMLDEPLKLLIHD-UHFFFAOYSA-N 0.000 claims 1
- KSYMELKKLOFABL-UHFFFAOYSA-N 2-(5-chloro-2-methyl-1h-indol-3-yl)-n,n-dimethylethanamine Chemical compound C1=C(Cl)C=C2C(CCN(C)C)=C(C)NC2=C1 KSYMELKKLOFABL-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000011987 methylation Effects 0.000 claims 1
- 238000007069 methylation reaction Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 230000000862 serotonergic effect Effects 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 201000003102 mental depression Diseases 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2001RM000356A ITRM20010356A1 (it) | 2001-06-21 | 2001-06-21 | "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina. |
| PCT/IT2002/000398 WO2003000252A1 (en) | 2001-06-21 | 2002-06-17 | 5-halo-tryptamine derivatives used as ligands of the 5-ht6 and/or 5-ht7 serotonin receptors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010204733A Division JP2011016835A (ja) | 2001-06-21 | 2010-09-13 | ５−ｈｔ６および／または５−ｈｔ７セロトニン受容体のリガンドとして使用される５−ハロ−トリプタミン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004534816A JP2004534816A (ja) | 2004-11-18 |
| JP2004534816A5 true JP2004534816A5 (enExample) | 2010-11-18 |
| JP4683839B2 JP4683839B2 (ja) | 2011-05-18 |
Family
ID=11455609
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003506898A Expired - Fee Related JP4683839B2 (ja) | 2001-06-21 | 2002-06-17 | ５−ｈｔ６および／または５−ｈｔ７セロトニン受容体のリガンドとして使用される５−ハロ−トリプタミン誘導体 |
| JP2010204733A Pending JP2011016835A (ja) | 2001-06-21 | 2010-09-13 | ５−ｈｔ６および／または５−ｈｔ７セロトニン受容体のリガンドとして使用される５−ハロ−トリプタミン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010204733A Pending JP2011016835A (ja) | 2001-06-21 | 2010-09-13 | ５−ｈｔ６および／または５−ｈｔ７セロトニン受容体のリガンドとして使用される５−ハロ−トリプタミン誘導体 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7098233B2 (enExample) |
| EP (1) | EP1404317B1 (enExample) |
| JP (2) | JP4683839B2 (enExample) |
| KR (1) | KR100885308B1 (enExample) |
| CN (1) | CN100482223C (enExample) |
| AT (1) | ATE416767T1 (enExample) |
| AU (1) | AU2002317482B2 (enExample) |
| BR (1) | BR0210538A (enExample) |
| CA (1) | CA2455296C (enExample) |
| CY (1) | CY1108879T1 (enExample) |
| CZ (1) | CZ20033314A3 (enExample) |
| DE (1) | DE60230270D1 (enExample) |
| DK (1) | DK1404317T3 (enExample) |
| ES (1) | ES2319107T3 (enExample) |
| HU (1) | HUP0400250A3 (enExample) |
| IT (1) | ITRM20010356A1 (enExample) |
| MX (1) | MXPA03011510A (enExample) |
| PL (1) | PL367618A1 (enExample) |
| PT (1) | PT1404317E (enExample) |
| SK (1) | SK287828B6 (enExample) |
| WO (1) | WO2003000252A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR039127A1 (es) * | 2002-03-27 | 2005-02-09 | Glaxo Group Ltd | Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento |
| NZ544331A (en) | 2003-07-22 | 2010-03-26 | Arena Pharm Inc | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
| US8086315B2 (en) | 2004-02-12 | 2011-12-27 | Asap Medical, Inc. | Cardiac stimulation apparatus and method for the control of hypertension |
| CA2557158A1 (en) * | 2004-02-20 | 2005-09-01 | Astellas Pharma Inc. | Prophylactic antimigraine agents |
| US20080171788A1 (en) * | 2005-02-08 | 2008-07-17 | Shinobu Akuzawa | Medicament For Irritable Bowel Syndrome |
| EP1923387B1 (en) | 2005-08-08 | 2011-10-19 | Astellas Pharma Inc. | Acylguanidine derivative or salt thereof |
| WO2007046112A1 (en) * | 2005-10-19 | 2007-04-26 | Suven Life Sciences Inc. | Arylthioether tryptamine derivatives as functional 5-ht6 ligands |
| WO2007097276A1 (ja) * | 2006-02-20 | 2007-08-30 | Astellas Pharma Inc. | ピロール誘導体またはその塩 |
| EP2120950B1 (en) * | 2007-03-21 | 2012-07-04 | Glaxo Group Limited | Use of quinoline derivatives in the treatment of pain |
| EP2209380A4 (en) * | 2007-10-09 | 2011-09-14 | Mark T Hamann | METHOD OF USE OF COMPOSITIONS WITH ANTIDEPRESSIVE EFFICACY, MOOD EFFICACY AND OTHER NEUROLOGICAL EFFECTIVENESS AND COMPOSITIONS THEREOF |
| EP2254564A1 (en) | 2007-12-12 | 2010-12-01 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
| WO2009123714A2 (en) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
| CA2842455A1 (en) * | 2011-08-05 | 2013-02-14 | Sucampo Ag | Method for treating schizophrenia |
| CN102816103B (zh) * | 2012-08-20 | 2014-05-07 | 冉瑞琼 | 硫化天冬氨酸修饰的退黑素衍生物及其应用 |
| US9008769B2 (en) | 2012-12-21 | 2015-04-14 | Backbeat Medical, Inc. | Methods and systems for lowering blood pressure through reduction of ventricle filling |
| US9370662B2 (en) | 2013-12-19 | 2016-06-21 | Backbeat Medical, Inc. | Methods and systems for controlling blood pressure by controlling atrial pressure |
| CN104529865B (zh) * | 2014-12-12 | 2017-02-01 | 广东东阳光药业有限公司 | 苄胺类衍生物及其在药物上的应用 |
| JP2018516992A (ja) | 2015-06-12 | 2018-06-28 | アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ | レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体 |
| CN108472285A (zh) | 2015-07-15 | 2018-08-31 | 阿速万科学有限责任公司 | 用于预防和治疗与神经退行性疾病相关联的幻觉的二芳基和芳基杂芳基脲衍生物 |
| US10342982B2 (en) | 2015-09-11 | 2019-07-09 | Backbeat Medical, Inc. | Methods and systems for treating cardiac malfunction |
| US10485658B2 (en) | 2016-04-22 | 2019-11-26 | Backbeat Medical, Inc. | Methods and systems for controlling blood pressure |
| CN108926565A (zh) * | 2017-05-26 | 2018-12-04 | 中国科学院上海生命科学研究院 | 五羟色胺受体亚型6小分子激活剂及拮抗剂在防治阿尔茨海默症中的应用 |
| EP3813810A4 (en) * | 2018-06-21 | 2022-03-30 | Robert John Petcavich | METHODS OF INDUCING DENDRITICAL AND SYNAPTIC GENESIS IN CHRONIC NEURODEGENERATIVE DISEASES |
| GB201907871D0 (en) * | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| LT4084791T (lt) * | 2020-02-18 | 2025-02-25 | Gilgamesh Pharmaceuticals, Inc. | Specifiniai triptaminai, skirti nuotaikos sutrikimams gydyti |
| IL297861A (en) | 2020-05-08 | 2023-01-01 | Psilera Inc | Novel compositions of matter and pharmaceutical compositions |
| IL312785B2 (en) | 2020-05-19 | 2026-06-01 | Cybin Irl Ltd | Deuterated tryptamine derivatives and methods of use |
| WO2021116503A2 (en) * | 2020-06-02 | 2021-06-17 | Small Pharma Ltd | Deuterated compounds |
| WO2022061196A1 (en) * | 2020-09-18 | 2022-03-24 | Mydecine Innovations Group Inc. | Novel formulations of psilocybin and psilocin compounds as serotonin agonists in combination with 3,4 methylenedioxymethamphetamine (mdma) |
| KR20240013170A (ko) | 2021-05-25 | 2024-01-30 | 아타이 테라퓨틱스, 인크. | 신규 n,n-디메틸트립타민 염 및 결정질 염 형태 |
| IL309210A (en) | 2021-06-09 | 2024-02-01 | Atai Therapeutics Inc | Parent drugs and conjugates of dimethyltryptamine |
| US20240343692A1 (en) * | 2021-08-09 | 2024-10-17 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Selective psychedelic compounds |
| CA3238440A1 (en) * | 2021-12-30 | 2023-07-06 | Atai Therapeutics, Inc. | Dimethyltryptamine analogues as nitric oxide delivery drugs |
| CN114573578B (zh) * | 2022-02-16 | 2023-11-17 | 烟台宁远药业有限公司 | 一种烷基取代氮杂吲哚的制备方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2825734A (en) * | 1955-04-11 | 1958-03-04 | Upjohn Co | Reduction of carbonylic radicals in indolyl-3 compounds |
| GB966562A (en) * | 1961-04-06 | 1964-08-12 | Parke Davis & Co | Amine compounds and means of producing the same |
| FR2315277A1 (fr) * | 1975-06-25 | 1977-01-21 | Anvar | Nouveaux derives pentacycliques, leur preparation et les compositions qui les contiennent |
| US4428877A (en) * | 1978-07-12 | 1984-01-31 | Richter Gedeon Vegyeszeti Gyar Rt. | Cis-10-bromo-E-homoeburnanes |
| GB8531612D0 (en) * | 1985-12-23 | 1986-02-05 | Beecham Wuelfing Gmbh & Co Kg | Compounds |
| US5300645A (en) * | 1993-04-14 | 1994-04-05 | Eli Lilly And Company | Tetrahydro-pyrido-indole |
| FR2712591B1 (fr) * | 1993-11-19 | 1996-02-09 | Pf Medicament | Nouvelles arylpipérazines dérivées d'indole, leur préparation et leur utilisation thérapeutique. |
| US5688807A (en) * | 1994-03-11 | 1997-11-18 | Eli Lilly And Company | Method for treating 5HT2B receptor related conditions |
| US5504101A (en) * | 1994-05-06 | 1996-04-02 | Allelix Biopharmaceuticals, Inc. | 5-HT-1D receptor ligands |
| WO1998000400A1 (en) * | 1996-06-28 | 1998-01-08 | Meiji Seika Kaisha, Ltd. | Tetrahydrobenzindole compounds |
| US6100291A (en) * | 1998-03-16 | 2000-08-08 | Allelix Biopharmaceuticals Inc. | Pyrrolidine-indole compounds having 5-HT6 affinity |
| US6251893B1 (en) * | 1998-06-15 | 2001-06-26 | Nps Allelix Corp. | Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity |
| AU767009B2 (en) * | 1998-12-11 | 2003-10-30 | Virginia Commonwealth University | Selective 5-HT6 receptor ligands |
| US6403808B1 (en) * | 1999-12-10 | 2002-06-11 | Virginia Commonwealth University | Selective 5-HT6 receptor ligands |
| EP1173432B9 (en) * | 1999-04-21 | 2008-10-15 | NPS Allelix Corp. | Piperidine-indole compounds having 5-ht6 affinity |
| AU779832B2 (en) | 1999-08-12 | 2005-02-10 | Nps Pharmaceuticals, Inc. | Azaindoles having serotonin receptor affinity |
| WO2004041781A1 (en) * | 2002-11-07 | 2004-05-21 | Suven Life Sciences Limited | Preparation of 3-aminoalkyl-substituted indole derivatives from phenylhydrazines and aminoketones |
-
2001
- 2001-06-21 IT IT2001RM000356A patent/ITRM20010356A1/it unknown
-
2002
- 2002-06-17 PL PL02367618A patent/PL367618A1/xx not_active IP Right Cessation
- 2002-06-17 CZ CZ20033314A patent/CZ20033314A3/cs unknown
- 2002-06-17 CN CNB02814337XA patent/CN100482223C/zh not_active Expired - Fee Related
- 2002-06-17 AU AU2002317482A patent/AU2002317482B2/en not_active Ceased
- 2002-06-17 MX MXPA03011510A patent/MXPA03011510A/es active IP Right Grant
- 2002-06-17 EP EP02745793A patent/EP1404317B1/en not_active Expired - Lifetime
- 2002-06-17 AT AT02745793T patent/ATE416767T1/de active
- 2002-06-17 SK SK38-2004A patent/SK287828B6/sk not_active IP Right Cessation
- 2002-06-17 KR KR1020037016564A patent/KR100885308B1/ko not_active Expired - Fee Related
- 2002-06-17 PT PT02745793T patent/PT1404317E/pt unknown
- 2002-06-17 DE DE60230270T patent/DE60230270D1/de not_active Expired - Lifetime
- 2002-06-17 ES ES02745793T patent/ES2319107T3/es not_active Expired - Lifetime
- 2002-06-17 US US10/481,433 patent/US7098233B2/en not_active Expired - Fee Related
- 2002-06-17 DK DK02745793T patent/DK1404317T3/da active
- 2002-06-17 CA CA2455296A patent/CA2455296C/en not_active Expired - Fee Related
- 2002-06-17 JP JP2003506898A patent/JP4683839B2/ja not_active Expired - Fee Related
- 2002-06-17 BR BR0210538-1A patent/BR0210538A/pt not_active Application Discontinuation
- 2002-06-17 HU HU0400250A patent/HUP0400250A3/hu unknown
- 2002-06-17 WO PCT/IT2002/000398 patent/WO2003000252A1/en not_active Ceased
-
2009
- 2009-03-06 CY CY20091100260T patent/CY1108879T1/el unknown
-
2010
- 2010-09-13 JP JP2010204733A patent/JP2011016835A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2455296A1 (en) | 5-halo-tryptamine derivatives used as ligands of the 5-ht6 and/or 5-ht7 serotonin receptors | |
| AU2013337742B2 (en) | 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto | |
| MY138252A (en) | Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease | |
| JP2007508360A5 (enExample) | ||
| JP2004534850A5 (enExample) | ||
| EP1740581A4 (en) | ALSHEETS INHIBITORS SUITABLE FOR THE TREATMENT OF ALZHEIMER DISEASE: 2,4,6-SUBSTITUTED PYRIDYL DERIVATIVE COMPOUNDS | |
| EA016687B8 (ru) | Производные циклопропиламида | |
| JP2018537535A5 (enExample) | ||
| EP1740559A4 (en) | ALSHEETS INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE SUITABLE 1,3,5-SUBSTITUTED PHENYL DERIVATIVE COMPOUNDS | |
| RU2010119560A (ru) | Замещенные n-фенилбипирролидинкарбоксамиды и их терапевтическое применение | |
| JP2022539152A5 (enExample) | ||
| JP2015508092A5 (enExample) | ||
| JP2005508872A5 (enExample) | ||
| JP2016522254A5 (enExample) | ||
| JP2010521516A5 (enExample) | ||
| JP2010522711A5 (enExample) | ||
| JP2004502755A5 (enExample) | ||
| EP1807396A4 (en) | 2-AMINOPYRIDINE COMPOSITIONS AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF MORBUS ALZHEIMER | |
| DE60221283D1 (de) | Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden | |
| CA2498291A1 (en) | Diazabicyclic compounds useful in the treatment of cns and other disorders | |
| JP2004527492A5 (enExample) | ||
| DE602004005502D1 (de) | Comt-inhibitoren | |
| EP1910321A4 (en) | NEW COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF, INTERMEDIATE PRODUCTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OF 5-HT6-MEDIATED ILLNESSES SUCH AS ALZHEIMER'S DISEASE, COGNITIVE ILLUSTRATIONS, SCHOISOPHRENIC ASSOCIATED COGNITIVE DISORDERS, OBESITAS AND PARKINSON DISEASE | |
| JP2005500370A5 (enExample) | ||
| TW200612937A (en) | 4-hydroxy-4-methyl-piperidine-1-carboxylic acid(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide |